Evidence map›Paper›PMID 26607265›Full record

ArticleImmunologic research2016

Construction of recombinant Mip-FlaA dominant epitope vaccine against Legionella pneumophila and evaluation of the immunogenicity and protective immunity.

Jinlei He, Junrong Zhang, Yanxia He, Fan Huang, Jiao Li, Qiwei Chen, Dali Chen, Jianping Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A Rapid and Sensitive CRISPR-Cas12a for the Detection ofPolish journal of microbiology · 2025
    Article
  2. [Construction and Expression of Eukaryotic and Prokaryotic Recombinant Vectors ofSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinlei HeDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Junrong ZhangDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Yanxia HeDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Fan HuangFirst Department of Hepatobiliary Surgery, Qinghai University Affiliated Hospital, Medical College of Qinghai University, Xining, 810016, China.
Jiao LiDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Qiwei ChenDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Dali ChenDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Jianping ChenDepartment of Parasitology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, 610041, China. jianpc007@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Legionnaires' disease, a kind of systemic disease with pneumonia as the main manifestation, is caused by Legionella pneumophila (L. pneumophila). In order to prevent the disease, we optimized Mip and FlaA, the virulence factors of L. pneumophila, to design recombinant Mip-FlaA dominant epitope vaccine against the pathogen. Firstly, the coding sequences of mip and flaA were optimized by DNAStar software and Expasy protein analysis system, and then, the tertiary structure and function of recombinant Mip-FlaA were predicted by PHYRE2 Protein Fold Recognition Server. After that, the optimized mip, flaA and mip-flaA were cloned, expressed and purified, and the proteins were used as dominant epitope vaccines to immunize BABL/c mice. Moreover, the IgG titers, histological changes in lung and the level of TNF-α, IFN-γ, IL-6 and IL-1β were detected to reflect the immunogenicity and protective immunity of the vaccines. The results of SDS-PAGE and Western blot proved the recombinant Mip-FlaA was successfully expressed. ELISA results of IgG titers and these cytokines showed Mip-FlaA group was capable to induce the strongest immune response, compared to PBS, Mip and FlaA groups. In addition, histopathology analysis demonstrated the mice immunized with Mip-FlaA showed better immune protection. Therefore, the work indicated that the above-described biological tools were useful in optimization of epitope vaccine. Antigenic characterization and immune protection of recombinant Mip-FlaA would be of great value in understanding the immunopathogenesis of the disease and in developing possible vaccine against the pathogen.

Indexed as

Immunity, InnateAnimalsBacterial ProteinsBacterial VaccinesFemaleFlagellinHumansImmunodominant EpitopesLegionella pneumophilaLegionnaires' DiseaseMiceMice, Inbred BALB CPeptidylprolyl IsomeraseProtein EngineeringVaccines, SubunitVirulenceBacterial ProteinsBacterial VaccinesflaA protein, bacteriaFlagellinImmunodominant EpitopesMip protein, Legionella pneumophilaPeptidylprolyl IsomeraseVaccines, SubunitEpitope vaccineFlaAImmunityLegionella pneumophilaMip

Identifiers

PMID26607265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.